✨ Free AI Report
Centessa Pharmaceuticals plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Centessa Pharmaceuticals plc
Company Research

Centessa Pharmaceuticals plc: Business Overview, Financials & Competitive Analysis

Centessa Pharmaceuticals is a UK-based clinical-stage pharmaceutical company focused on discovering and developing transformational medicines. The company's primary focus is on orexin receptor 2 (OX2R) agonists for sl...

Analyst-debate audio for Centessa Pharmaceuticals plc

AskCyborg analysts argue the bull and bear cases for Centessa Pharmaceuticals plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Focused orexin agonist platform with meaningful clinical validation and multi-indication expansion potential offers attractive...

Read the full analyst-debate transcript →
Industry Clinical-stage Pharmaceutical/Biotech - Neurology Focus
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Centessa Pharmaceuticals plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Centessa Pharmaceuticals plc Overview

Pro stress-test →

Centessa Pharmaceuticals is a UK-based clinical-stage pharmaceutical company focused on discovering and developing transformational medicines. The company's primary focus is on orexin receptor 2 (OX2R) agonists for sleep-wake disorders and other neurological conditions, with its lead program ORX750 in Phase 2a development.

Strategic Profile

Pro stress-test →

Centessa leverages a differentiated orexin agonist platform with multiple programs targeting significant unmet medical needs in sleep disorders, neurodegeneration, and neuropsychiatric conditions. The company also maintains an immuno-oncology program via its LockBody technology platform, providing pipeline diversification beyond its core orexin focus.

Competitive Landscape

Pro stress-test →

Centessa competes in the sleep disorder and neuropsychiatric pharmaceuticals space against larger biotech firms and specialized neurology companies developing similar symptom-targeting therapies. The company's orexin agonist approach differentiates it from traditional monoamine-based treatments, positioning it in an emerging category with limited direct competitors at similar clinical stages.

Industry Context

Centessa Pharmaceuticals plc operates in Clinical-stage Pharmaceutical/Biotech - Neurology Focus.

Key facts

Founded: 2020 · Headquarters: Altrincham, UK

What the analysts stress-tested

The top findings that survived the multi-agent debate for Centessa Pharmaceuticals plc.

  • Lead program ORX750 advancing in Phase 2a for narcolepsy and idiopathic hypersomnia with positive animal model data showing antidepressive effects
  • Broader orexin platform addresses large neurological/neuropsychiatric markets with multiple shots on goal including ORX142 and ORX489
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026ORX489 Phase 1 trial early safety readout anticipated
  • Feb 2026New CEO transition completed with program founder appointed to lead company
  • +2 moreTrack every material event for Centessa Pharmaceuticals plc as it happens. Explore monitoring →
Get alerted when Centessa Pharmaceuticals plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Wakix (pitolisant)Histamine H3-receptor antagonist for narcolepsy→XywavSodium oxybate for narcolepsy and IH→Sunosi (solriamfetol)Dopamine/norepinephrine reuptake inhibitor for EDS→

Compare Centessa Pharmaceuticals plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Centessa Pharmaceuticals plc operates in Clinical-stage Pharmaceutical/Biotech - Neurology Focus. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage Pharmaceutical/Biotech - Neurology Focus research →
NEW · MCP server

Ask your AI assistant about Centessa Pharmaceuticals plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Centessa Pharmaceuticals plc and its top competitor on Cyborg Score”
“What did Centessa Pharmaceuticals plc do this quarter?”
“Is Centessa Pharmaceuticals plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Centessa Pharmaceuticals plc do?+
Centessa Pharmaceuticals is a UK-based clinical-stage pharmaceutical company focused on discovering and developing transformational medicines. The company's primary focus is on orexin receptor 2 (OX2R) agonists for sl...
What is Centessa Pharmaceuticals plc's Cyborg Score?+
Centessa Pharmaceuticals plc has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Centessa Pharmaceuticals plc's main competitors?+
Named competitors include Wakix (pitolisant), Xywav, Sunosi (solriamfetol). The full competitive landscape is in the AskCyborg report.
How can I get the full Centessa Pharmaceuticals plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Centessa Pharmaceuticals plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Centessa Pharmaceuticals plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.